CASTLE BIOSCIENCES INC Material Event - What Happened

Hey there! Let's break down what's going on with CASTLE BIOSCIENCES INC in a way that makes sense, without all the fancy finance talk. Think of this as me explaining it to you over coffee.

---

1. What happened? (The actual event, in plain English)

So, what's the big news? Castle Biosciences Inc. just shared some early numbers about how well they did financially in the last three months of 2025 (that's the fourth quarter) and for the entire year of 2025. These are "preliminary" results, meaning they're not the final, audited numbers yet, but they give us a good sneak peek into their performance.

And here's the exciting part: these preliminary results are looking really good! The company expects its total revenue for 2025 to be over $340 million, which is actually higher than what they had previously told everyone to expect (their guidance was $327-335 million). Plus, the number of core tests they processed (DecisionDx-Melanoma and TissueCypher) jumped by a significant 37% compared to 2024. They also ended the year with a healthy chunk of cash and investments, around $300 million.

2. When did it happen?

This all went down on January 11, 2026. The company officially announced it in a press release and also made a slide presentation available with more details.

3. Why did it happen? (Context and background)

To understand why this happened, you need to know a little background. Companies like Castle Biosciences regularly update investors on their financial health. It's standard practice for publicly traded companies to release preliminary results before their full, official earnings report. This gives everyone an early look at how the business performed, especially as the year just wrapped up.

In this case, the company's CEO, Derek Maetzold, sounded "extremely pleased" with these results, highlighting the strength of their tests and the team's hard work. It wasn't completely out of the blue, but the fact that they exceeded their own expectations definitely changes things in a positive way.

4. Why does this matter? (Impact and significance)

Okay, so why should you care? This is a big deal because these preliminary results give us the first real indication of how the company finished the year financially, and the news is very positive. When a company beats its own financial predictions, it usually signals strong growth, good management, and a healthy business.

It helps investors and analysts start forming their opinions about the company's performance and future prospects even before the final, official report comes out. Good news like this can really boost confidence in the company and its future.

5. Who is affected?

Who's feeling this? Pretty much everyone connected to the company:

• Investors (that's us!): Our shares might go up or down depending on how people react to these early numbers. Good numbers usually mean happy investors, and in this case, the numbers are looking great!
• Employees: Strong results can boost morale and job security, making everyone feel more confident about the company's direction.
• Customers/Patients: A financially healthy company can continue to innovate, develop new tests, and provide better services, which ultimately benefits patients.
• Competitors: They'll be watching closely to see how Castle Biosciences is performing, which can influence their own strategies. These strong results show Castle Biosciences is a formidable player.

6. What happens next? (Immediate and future implications)

So, what's on the horizon? What can we expect next?

• Immediately: The stock price is likely to react positively to these strong preliminary numbers. Investors and analysts will be digging into the details from the press release and slide presentation. The company will also likely hold an earnings call soon to discuss these results in more detail and answer questions.
• In the future: These preliminary results will be followed by the official, audited financial report, usually within a few weeks or months. That report will confirm these numbers (though they're usually very close to the preliminary ones) and provide even more detailed insights into the company's performance and outlook for the next year. There will definitely be more news to follow.

7. What should investors/traders know? (Practical takeaways)

Alright, for those of us looking at our portfolios, here's the lowdown:

• Positive Outlook: The preliminary numbers are strong, with revenue exceeding guidance and significant growth in core test volumes. This is generally very good news for the stock.
• Volatility Alert: Even with good news, the stock price can still be a bit of a roller coaster as the market digests the information. Big news often causes big swings, but likely with an upward bias in this case.
• Look for the Details: Don't just react to headlines. The company reported:
  • 2025 Revenue: Expected to be over $340 million (beating their own forecast of $327-335 million).
  • Core Test Growth: Total test reports for their main tests (DecisionDx-Melanoma, TissueCypher) increased 37% in 2025 over 2024. In the last quarter of 2025 alone, these core tests grew 42% compared to the same quarter in 2024.
  • Specific Test Performance:
    • DecisionDx-Melanoma: Saw good growth, with 10,022 tests in Q4 2025 and 39,083 for the full year.
    • TissueCypher Barrett’s Esophagus: Showed impressive growth, with 11,803 tests in Q4 2025 and 39,014 for the full year.
    • New Test Launch (AdvanceAD-Tx): They launched a new test in November 2025 for atopic dermatitis, and over half of the doctors who got early access ordered it within the first five weeks – a promising start!
    • Other Tests: While some tests like DecisionDx-SCC and DecisionDx-UM saw slight dips in Q4 (due to things like Medicare coverage changes or commercial refocus), their full-year numbers were still up or stable. They also discontinued an older test (IDgenetix) in May 2025, which explains its lower numbers.
  • Strong Cash Position: They ended 2025 with about $300 million in cash and investments, which is a solid financial cushion.
• Preliminary Means Preliminary: Remember these aren't final. While usually very close, there's a small chance they could change slightly in the final report.
• Consider Your Strategy: If you own shares, this news likely reinforces a positive outlook. If you're thinking of buying, weigh the potential upsides against the risks, now with the context of strong performance.
• Stay Tuned: Keep an eye out for the full, official earnings report and any investor calls where management will discuss these results in depth.